Ausbiz Interview
Althea CEO Josh Fegan recently caught up with the team from Ausbiz to discuss many of the opportunities and challenges that face the medicinal cannabis industry. During…
read moreAustralian pharmaceutical company Althea Group Holdings Limited (ASX:AGH) (‘Althea’ or ‘the Company’) is pleased to announce it has executed a Medicinal Cannabis…
read more
Althea CEO Josh Fegan recently caught up with the team from Ausbiz to discuss many of the opportunities and challenges that face the medicinal cannabis industry. During…
read moreInvestment Highlights: Althea has executed a three-year Supply and Distribution Agreement with Nimbus Health GmbH. Nimbus Health is a renowned player in the German…
read moreInvestment Highlights: Althea achieved unaudited revenue of $1,524,359 for the quarter ended 31 March 2020, up 39% from the December quarter Cash receipts from…
read moreAlthea is dedicated to supporting healthcare providers seeking information about and access to medicinal cannabis as a treatment option for eligible patients. One of the ways we connect with healthcare providers is by attending conferences and arranging education events.
View More Events
The growth continues! Althea has officially reached over 5,000 patients. This is an exciting milestone and a great reflection of the relentless hard work from all of the team. Thank you to all our fantastic partners and we look forward to further continued growth in 2020. https://t.co/itYfbPQHZn
read moreOur CEO Josh Fegan sat down with @CommSec's Tom Piotrowski to discuss our focus on education & technology to improve patient access to medicinal cannabis & the positive regulatory outlook for new jurisdictions & emerging markets | Video: http://ow.ly/BTEj50v0x8C
read moreAlthea is thrilled to announce that we will supply the first UK national medical cannabis pilot targeting 20,000 patients | Read the ASX announcement here: https://www.asx.com.au/asxpdf/20190625/pdf/4462xcgx974f62.pdf $AGH
read more
©2020 Althea Company Pty Ltd
